Top Clinical Trials companies in France by Return on Assets (ROA)
France
# |
Name |
Return on Assets (ROA) |
Reported Date | Stock Price |
Change |
Price (30 days) | Country |
|---|---|---|---|---|---|---|---|
| 1 |
-16.62%
|
Dec. 31, 2023 | USD 3.82 | 3.95% |
|
France |
|
| 2 |
-22.12%
|
Dec. 31, 2023 | USD 1.42 | -2.42% |
|
France |
|
| 3 |
-28.03%
|
Dec. 31, 2023 | USD 6.91 | 1.86% |
|
France |
|
| 4 |
-30.16%
|
Dec. 31, 2023 | USD 2.14 | -0.29% |
|
France |
|
| 5 |
-30.23%
|
Dec. 31, 2023 | USD 1.58 | 0.37% |
|
France |
|
| 6 |
-39.74%
|
Dec. 31, 2023 | USD 4.26 | 0.95% |
|
France |
|
| 7 |
-45.17%
|
Dec. 31, 2023 | USD 6.10 | -0.29% |
|
France |
|
| 8 |
-45.93%
|
Dec. 31, 2023 | USD 8.25 | -0.54% |
|
France |
|
| 9 |
-67.77%
|
March 31, 2024 | USD 16.15 | -3.27% |
|
France |
|
| 10 |
-84.80%
|
Dec. 31, 2023 | USD 6.11 | -1.79% |
|
France |
|
| 11 |
-158.75%
|
Dec. 31, 2023 | USD 2.41 | 7.10% |
|
France |
Frequently Asked Questions
-
Which Clinical Trials company in France has the highest Return on Assets (ROA) ?
The Clinical Trials company in France with the highest Return on Assets (ROA) is Genfit S.A. (Paris Stock Exchange: GNFT.PA) at -16.62%.
-
Which Clinical Trials company in France has the lowest Return on Assets (ROA) ?
The Clinical Trials company in France with the lowest Return on Assets (ROA) is Inventiva S.A. (Paris Stock Exchange: IVA.PA) at -158.75%.
-
What are the top 10 Clinical Trials companies in France by Return on Assets (ROA) ?
The top 10 Clinical Trials companies in France by Return on Assets (ROA) are Genfit S.A., Valbiotis SA, OSE Immunotherapeutics SA, Crossject SA, Cellectis S.A., DBV Technologies S.A., ABIVAX SA, MaaT Pharma SA, MedinCell S.A. and Adocia SA.
-
What are the bottom 10 Clinical Trials companies in France by Return on Assets (ROA) ?
The bottom 10 Clinical Trials companies in France by Return on Assets (ROA) are Inventiva S.A., Adocia SA, MedinCell S.A., MaaT Pharma SA, ABIVAX SA, DBV Technologies S.A., Cellectis S.A., Crossject SA, OSE Immunotherapeutics SA and Valbiotis SA.
